Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay buffalo, ny – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park…
ASCO has released recommendations to streamline serious adverse events reporting for cancer clinical trials.https://t.co/RZZEbw2eJB
Pazdur: “Clinical trials are here to serve patients. Patients are not here to serve clinical trials.” Make it true.
The crowd is gathering for the grand opening ceremony for #UBuffalo’s new Jacobs School of Medicine and Biomedical Sciences building! We will live tweet from today’s event shortly.
Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors. - Fast track is safe and effective https://t.co/geccewzJJC
We’re proud to announce the first-ever independent analysis of global immuno-oncology drug development. #immunotherapy
#JITC Review: #Biomarkers for immunotherapy in bladder cancer: a moving target https://t.co/8etuwbik01
"Predicting response...to #immunotherapy - and perhaps combination immunotherapy with chemotherapy and radiation therapy – may require a more profound deconvolution of the immunological tumor microenvironment." Read more here: https://t.co/Hxu5slZNjI